Key Developments: Catalyst Pharmaceutical Partners Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.96USD
26 Dec 2014
Price Change (% chg)

$0.06 (+2.07%)
Prev Close
$2.90
Open
$2.92
Day's High
$2.97
Day's Low
$2.92
Volume
42,560
Avg. Vol
224,902
52-wk High
$3.49
52-wk Low
$1.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceuticals Partners Inc proposes settlement of pending securities class action lawsuit
Tuesday, 4 Nov 2014 08:03am EST 

Catalyst Pharmaceuticals Partners Inc:Says that it has entered into a memorandum of understanding to settle its pending class action securities lawsuit.As previously disclosed, the company and one of its executive officers are defendants in a class action lawsuit filed in the U.S. District Court for the Southern District of Florida.Amended complaint purports to state a claim for alleged misrepresentations regarding the development of Firdapse(tm) on behalf of a class of those who purchased shares of the company's common stock between Aug. 27, 2013 and Oct. 18, 2013.  Full Article

Catalyst Pharmaceuticals Partners Inc announces positive top-line Phase 3 data from Pivotal Firdapse clinical trial
Monday, 29 Sep 2014 04:03pm EDT 

Catalyst Pharmaceuticals Partners Inc:Says positive top-line results from the pivotal Phase 3 clinical trial of Firdapse (amifampridine phosphate tablets equivalent to 10 mg amifampridine) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS).Both co-primary endpoints, quantitative myasthenia gravis score (QMG) and subject global impression (SGI), demonstrated that Firdapse was significantly superior to placebo, as did a secondary endpoint for the physician's clinical global impression of improvement.  Full Article

Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
Tuesday, 2 Sep 2014 08:03am EDT 

Catalyst Pharmaceutical Partners Inc:Says initiation of its second Phase 1 safety and tolerance study for CPP-115, a novel GABA aminotransferase (GABA-AT) inhibitor.Phase 1(b) trial is designed in 2 parts to evaluate the safety and tolerability of single and multiple doses of CPP-115, including CNS side effects, and respiratory and cardiovascular safety.  Full Article

Catalyst Pharmaceutical Partners Inc announces closing of public offering
Tuesday, 8 Apr 2014 10:30am EDT 

Catalyst Pharmaceutical Partners Inc:Closes public offering of shares of common stock.Company sold 13,023,750 shares of common stock in offering, including 1,698,750 shares that were issued upon exercise by underwriters of their overallotment option.Offering price was $2.21 per share, and net proceeds from sale of shares is expected to be $26.8 mln.Piper Jaffray & Co. acted as sole book-running manager for offering, Roth Capital Partners acted as co-lead manager, and H.C. Wainwright & Co., LLC acted as co-manager with respect to offering.  Full Article

Catalyst Pharmaceutical Partners prices public offering of common stock
Thursday, 3 Apr 2014 09:00am EDT 

Catalyst Pharmaceutical Partners Inc:Prices underwritten public offering of 11,325,000 shares of common stock at $2.21 per share.Grantes underwriters a 30-day option to purchase up to an additional 1,698,750 shares to cover over-allotments.Expects net proceeds to be about $23.3 mln.To use net proceeds for development of Firdapse or LEMS for pre-commercialization activities relating to Firdapse, for development of CPP-115 and for general corporate purposes.Expected to close on April 8.Piper Jaffray & Co is sole book-running manager.Roth Capital Partners co-lead manager.H.C. Wainwright & Co LLC is co-manager.  Full Article

Catalyst Pharmaceutical Partners Inc announces commencement of public offering of common stock
Wednesday, 2 Apr 2014 04:04pm EDT 

Catalyst Pharmaceutical Partners Inc:Intends to offer shares of its common stock in a public offering.Plans to use net proceeds from offering for continuing development of Firdapse for treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS.For pre-commercialization activities relating to Firdapse.Forcontinuing development of CPP-115and for general corporate purposes.Piper Jaffray & Co. is acting as the sole book-running manager.  Full Article

Catalyst Pharmaceutical Partners Inc announces recommendation of data monitoring committee to continue pivotal phase three clinical trial for firdapse
Tuesday, 25 Mar 2014 08:03am EDT 

Catalyst Pharmaceutical Partners Inc:At a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing its ongoing pivotal Phase three clinical trial evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).Recommended that the trial be continued as planned based on the committee's review of safety and clinical data from the trial.The international, multicenter Firdapse phase three clinical trial is designed as a randomized, double-blind, placebo-controlled, discontinuation trial enrolling 36 patients diagnosed with LEMS.The trial is being conducted at 22 centers in the United States, Canada, South America and Europe.  Full Article

Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Catalyst Pharmaceutical Partners Inc
Tuesday, 12 Nov 2013 07:15pm EST 

Glancy Binkow & Goldberg LLP announced that a class action lawsuit has been filed in the United States District Court for the Southern District of Florida on behalf of a class (the Class) comprising all purchasers of the securities of Catalyst Pharmaceutical Partners Inc between October 31, 2012 and October 18, 2013, inclusive (the Class Period). The Complaint alleges that the defendants failed to disclose that one of Catalyst`s competitors - a private pharmaceutical company - has been manufacturing a drug biologically equivalent to Firdapse, and providing it to patients with LEMS, free of charge, through a compassionate use program. On October 18, 2013, an article published by The Street stated that Catalyst`s Firdapse was the same drug that its competitor has been manufacturing and providing in the U.S. for at least two decades.  Full Article

Investor Files Federal Securities Fraud Class Action Complaint Against Catalyst Pharmaceutical Partners Inc
Tuesday, 12 Nov 2013 06:25pm EST 

Shareholder rights law firm Robbins Arroyo LLP announced that an investor of Catalyst Pharmaceutical Partners Inc has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of Florida. The complaint alleges that the Company and certain of its officers violated the Securities and Exchange Act of 1934 between October 31, 2012 and October 18, 2013 (the Class Period). Catalyst is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The Company's lead drug candidate, Firdapse, is a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS); a rare, neuromuscular disease which causes progressive muscle weakness. According to the complaint, the Company made false and misleading failed statements and/or failed to disclose material adverse facts about the Company's business prospects. Specifically, the complaint alleges that Catalyst failed to disclose to investors that its competitor, Jacobus Pharmaceuticals, has for twenty years provided LEMS patients in the United States an equivalent to Firdapse, free of charge through an FDA approved compassionate use program. On October 18, 2013, The Street issued an article revealing Jacobus' free alterative to Catalyst's Firdapse. On this news, Catalyst shares fell to $1.52 or 25% on October 21, 2013.  Full Article

Rigrodsky & Long, P.A. Announces Class Action Lawsuit Filed Against Catalyst Pharmaceutical Partners, Inc
Monday, 28 Oct 2013 04:58pm EDT 

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, announced that a complaint has been filed in the United States District Court for the Southern District of Florida on behalf of all persons or entities that purchased the common stock of Catalyst Pharmaceutical Partners, Inc. (Catalyst or the Company) between October 31, 2012 and October 18, 2013, inclusive (the Class Period), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the Complaint).  Full Article

UPDATE 1-Catalyst Pharma's lead drug succeeds in late-stage study

Sept 29 - Catalyst Pharmaceutical Partners Inc said its lead drug was found superior in treating symptoms associated with a rare autoimmune disorder, compared with a placebo.

Search Stocks